PDCD1 and metastatic melanoma: Immunotherapeutic antibodies directed at programmed cell‐death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen‐4 (CTLA‐4) are standard therapies for metastatic melanoma.1